Journal article

Study protocol of a phase 2, dual-centre, randomised, controlled trial evaluating the effectiveness of probiotic and egg oral immunotherapy at inducing desensitisation or sustained unresponsiveness (remission) in participants with egg allergy compared with placebo (Probiotic Egg Allergen Oral Immunotherapy for Treatment of Egg Allergy: PEAT study)

Paxton Loke, Adriana Chebar Lozinsky, Francesca Orsini, Lydia Su-Yin Wong, Agnes Sze-Yin Leung, Elizabeth Huiwen Tham, Andreas L Lopata, Lynette Pei-Chi Shek, Mimi LK Tang

BMJ OPEN | BMJ PUBLISHING GROUP | Published : 2021

Abstract

INTRODUCTION: Egg allergy is the most common food allergy in children but recent studies have shown persistence or delayed resolution into adolescence. As there is currently no effective long-term treatment, definitive treatments that improve quality of life and prevent fatalities for food allergies are required. We have previously shown that a novel treatment comprising a combination of the probiotic Lactobacillus rhamnosus CGMCC 1.3724 with peanut oral immunotherapy (OIT) is highly effective at inducing sustained unresponsiveness, with benefit persisting to 4 years after treatment cessation in the majority of initial treatment responders. In this study, we plan to extend the probiotic food..

View full abstract

Grants

Funding Acknowledgements

PEAT is an investigator-initiated study funded by a National Health and Medical Research Council (NHMRC) grant-Australia, Project Grant. The Murdoch Children's Research Institute is the sponsor of the study. The probiotic and placebo treatments were provided by Health World as in kind support. Health World had no input into the study design or in the decision to submit the paper for publication. The Murdoch Children's Research Institute is supported by the Victorian Government's Operational Infrastructure Support Program.